公开(公告)号：US20230405002A1

公开(公告)日：2023-12-21

申请号：US17904554

申请日：2021-02-22

Applicant: Pfizer Inc.

Inventor： Neeta Balkrishan Amin ,  Arthur James Bergman ,  Roberto Arnaldo Calle ,  Robert Gregory Dullea ,  David James Edmonds ,  William Paul Esler ,  Kevin James Filipski ,  James Richard Gosset ,  Albert Myung Kim ,  Jeffrey Allen Pfefferkorn ,  Patrick Robert Verhoest

IPC: A61K31/506 ,  A61K31/4545 ,  A61P1/16 ,  A61P3/04

CPC classification number: A61K31/506 ,  A61K31/4545 ,  A61P1/16 ,  A61P3/04

Abstract: Described herein are pharmaceutical compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto. Also described are compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto.

公开(公告)号：US20200071306A1

公开(公告)日：2020-03-05

申请号：US16553818

申请日：2019-08-28

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  C07D471/10

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US20160220557A1

公开(公告)日：2016-08-04

申请号：US15021010

申请日：2014-08-29

Applicant: PFIZER INC.

Inventor： William Paul Esler ,  Gabriele Elisabeth Sonnenberg

IPC: A61K31/4709

CPC classification number: A61K31/4709

Abstract: The present invention relates to methods of treating and/or preventing acne in patients comprising the step of administering to patients in need of such treatment a therapeutically effective amount of an ACC inhibitor or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及治疗和/或预防患者痤疮的方法，其包括向需要这种治疗的患者施用治疗有效量的ACC抑制剂或其药学上可接受的盐的步骤。

公开(公告)号：US12247022B2

公开(公告)日：2025-03-11

申请号：US17498256

申请日：2021-10-11

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  A61K45/06 ,  C07D471/10

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US20230218616A1

公开(公告)日：2023-07-13

申请号：US17904537

申请日：2021-02-22

Applicant: Pfizer Inc.

Inventor： Neeta Balkrishan Amin ,  Arthur James Bergman ,  Roberto Arnaldo Calle ,  William Paul Esler ,  Albert Myung Kim ,  Jeffrey Allen Pfefferkorn ,  Patrick Robert Verhoest

IPC: A61K31/506 ,  A61K31/438 ,  A61P1/16 ,  A61P3/00

CPC classification number: A61K31/506 ,  A61K31/438 ,  A61P1/16 ,  A61P3/00 ,  C07B2200/13

Abstract: A method for treating fatty liver disease and related diseases or disorders with a therapeutically effective amount of a composition comprising from about 25 mg to about 1200 mg of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or a pharmaceutically acceptable salt thereof, and from about 5 mg to about 40 mg of 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11254660B2

公开(公告)日：2022-02-22

申请号：US16553818

申请日：2019-08-28

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: C07D405/14 ,  C07D471/10 ,  A61K45/06

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.

公开(公告)号：US20220023299A1

公开(公告)日：2022-01-27

申请号：US17498256

申请日：2021-10-11

Applicant: Pfizer Inc.

Inventor： William Paul Esler ,  Trenton Thomas Ross

IPC: A61K31/506 ,  A61K31/438 ,  A61K9/00 ,  A61P1/16

Abstract: The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.